I know a thing or two about kidney health and diabetes. This is why I’m willing to bet that all 3 companies with SGLT-2 inhibitor drugs out there (Farxiga, Jardiance, and Invokana) are equally culpable when it comes to increasing the risk of amputation with this drug class. Now for the garage science: glucose is a large molecule and stretches-out the vessels in the body. Picture a colander full of grapes. The grapes are glucose molecules and your vessels are the colander. However, your vessels are more like tissue paper, not steel. Get the picture? SGLT-2 inhibitors make the body hold onto higher amounts of blood sugar before it gets peed-out. Higher levels of sugar in the blood are associated with diabetes complications like amputations. Imagine what high blood sugar is doing to the delicate vessels in your lower limbs. Now the FDA has advised JNJ, makers of Invokana, to label their SGLT-2 inhibitor with the stern warning. Why Johnson & Johnson first, you ask? Invokana is the #1 prescribed SGLT-2 inhibitor in the US. If I was a betting woman, I’d think LLY and AZN will be following suit with their drugs in this class, Jardiance and Farxiga. The path of least resistance is paved with amputation, apparently. Don’t walk that path until you know the full risks. Does this mean insulin is the safest choice for all people with diabetes? The word safe doesn’t belong anywhere in a life of diabetes. We’re all forced to play Russian roulette, every day. Let’s consume more product awareness, less processed sugars, and be in it to win it.
Help Dip a Stick for Diabetes, a 501(c)(3) nonprofit organization, achieve our mission to encourage everybody to know their diabetes status. Subscribe for free here or by texting DIPASTICK to 22828 and respond with your email. Shop Amazon and they pay the nonprofit for referring you. Donations can be made through PayPal.